Loading...

BCYC BICYCLE THERAPEUTICS PLC Product Launches 8-K Filing

BCYC

BCYC

BICYCLE THERAPEUTICS PLC

(BCYC)

2025 8-K

Management Change

Management Change

Financial Results

Board Appointments

Financial Statements

AGM Announcement

Financial Results

Trial Results Update

Financial Results

New Product Data

Clinical Results Update

Earnings Reports

Termination of Loan Agreement

Securities Purchase Agreement

Annual General Meeting

Earnings Reports

Management Changes

Financial Results and Direc...

Data Updates and R&D Strate...

Earnings Reports

Development Plan Announcement

Earnings Reports

Appointment of Officers

Equity Offering

Collaboration and License A...

Earnings Reports

Collaboration and License A...

Financial Results Announcement

Amendment to Employment Agr...

External Links:

Bicycle Therapeutics announced updated results from its Phase 1 trial of zelenectide pevedotin, showing a 65% overall response rate among patients, and highlighted strategic priorities for 2025.

AI Assistant

BICYCLE THERAPEUTICS PLC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.